Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Burande, Aksha_1_, Mahe, Etienne_1_, Nowell Fine2, Christopher Hahn4, Robert Miller2,  Lee, Holly_1_, McCulloch, Sylvia_1_, ,Tay Jason1,3, Duggan, Peter1, 1,3  and Jimenez-Zepeda,Victor1,3,

Main Body of the Abstract
Background: AL amyloidosis arises from accumulated light chains forming amyloid fibrils due to B-cell clone activity. Objectives In this study, we aimed to assess the role of a Monoclonal Gammopathy of Undetermined Significance (MGUS) clinic as potential group for the screening of amyloidosis. Methods Initially, we developed a biomarker driven screening based on fat pad aspirates and bone marrow biopsies for AL amyloidosis in cases with specific risk factors. Further, cardiac imaging studies were incorporated. Methods Retrospective chart reviews were completed for MGUS patients seen at the University of Calgary from 01/2013-01/2024. Those with abnormal free light chain ratios, amino terminal pro-brain natriuretic peptide (NTproBNP) >300 ng/L, albuminuria, heart failure, and/or non-diabetic neuropathy underwent fat pad aspirate alongside routine monoclonal investigations. Results In total, 244/418 patients underwent  bone marrow biopsies and  165 underwent fat pad aspirates.  Three patients were diagnosed with AL amyloidosis after presentation, one case was diagnosed and typed via fat pad aspirate. Further, 5 patients progressed to AL amyloidosis at a median of 107 months, 1 case with localized AL amyloidosis to the lung and 4 with systemic progression. 12 other cases were diagnosed with ATTR amyloidosis via cardiac biopsy in 3, fat pad aspirate in 1, knee tissue in 1, bladder in 1, bone marrow in 1 and 4 via transverse carpal ligament biopsy, 2 other patients declined biopsy. All cases had a positive pyrophosphate scan consistent with ATTR. Conclusion The study highlights the feasibility of amyloid screening in a MGUS clinic. However, better, and more sensitive biomarkers are required.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Burande, Aksha_1_, Mahe, Etienne_1_, Nowell Fine2, Christopher Hahn4, Robert Miller2,  Lee, Holly_1_, McCulloch, Sylvia_1_, ,Tay Jason1,3, Duggan, Peter1, _1,3_  and Jimenez-Zepeda,Victor1,3,

**Main Body of the Abstract**
**Background**: AL amyloidosis arises from accumulated light chains forming amyloid fibrils due to B-cell clone activity. **Objectives** In this study, we aimed to assess the role of a Monoclonal Gammopathy of Undetermined Significance (MGUS) clinic as potential group for the screening of amyloidosis. **Methods** Initially, we developed a biomarker driven screening based on fat pad aspirates and bone marrow biopsies for AL amyloidosis in cases with specific risk factors. Further, cardiac imaging studies were incorporated. **Methods** Retrospective chart reviews were completed for MGUS patients seen at the University of Calgary from 01/2013-01/2024. Those with abnormal free light chain ratios, amino terminal pro-brain natriuretic peptide (NTproBNP) >300 ng/L, albuminuria, heart failure, and/or non-diabetic neuropathy underwent fat pad aspirate alongside routine monoclonal investigations. **Results** In total, 244/418 patients underwent  bone marrow biopsies and  165 underwent fat pad aspirates.  Three patients were diagnosed with AL amyloidosis after presentation, one case was diagnosed and typed via fat pad aspirate. Further, 5 patients progressed to AL amyloidosis at a median of 107 months, 1 case with localized AL amyloidosis to the lung and 4 with systemic progression. 12 other cases were diagnosed with ATTR amyloidosis via cardiac biopsy in 3, fat pad aspirate in 1, knee tissue in 1, bladder in 1, bone marrow in 1 and 4 via transverse carpal ligament biopsy, 2 other patients declined biopsy. All cases had a positive pyrophosphate scan consistent with ATTR. **Conclusion** The study highlights the feasibility of amyloid screening in a MGUS clinic. However, better, and more sensitive biomarkers are required.

Role of Amyloidosis screening in a Monoclonal Gammopathy of Undetermined Signifcance (MGUS) clinic: Results from a pilot study at the University of Calgary PA63 (#308)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.